News
It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...
Roche envisions its Indianapolis site as a “major hub” for the manufacturing of its continuous glucose monitoring systems.
Found, the leading specialized weight care telehealth platform developed by obesity specialists, today announced it will offer Wegovy® at $499 per month and Zepbound™ vials ranging from $349 to $699.
GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...
Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...
Explore more
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...
A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their perceptions about the causes of obesity and treatment goals.
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...
Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) ...
Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results